anti-inflammatoty and immuno-therapy - versus standard of care - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.94 [0.74, 1.20]< 10%17 studies (17/-)69.3 %some concernlow moderatecrucial-
deaths 0.80 [0.68, 0.95]< 129%32 studies (32/-)99.4 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.73 [0.43, 1.26]< 170%6 studies (6/-)86.8 %highnot evaluable lowcrucial-
clinical deterioration 0.63 [0.45, 0.88]< 10%4 studies (4/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.57 [1.21, 2.05]> 164%12 studies (12/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.54 [1.05, 2.25]> 147%5 studies (5/-)98.6 %highnot evaluable lowimportant-
clinical improvement (28-day) 1.66 [0.75, 3.67]> 164%4 studies (4/-)89.5 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 2.47 [0.37, 16.27]> 172%2 studies (2/-)82.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.60 [1.11, 2.31]> 128%5 studies (5/-)99.4 %some concernserious moderateimportant-
death or ventilation 1.31 [0.69, 2.46]< 156%4 studies (4/-)20.4 %highnot evaluable lowimportant-
hospital discharge 2.24 [0.99, 5.10]> 10%2 studies (2/-)97.3 %highnot evaluable lowimportant-
mechanical ventilation 0.98 [0.65, 1.47]< 10%9 studies (9/-)53.9 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 10%1 study (1/-)80.2 %NAnot evaluable important-
radiologic improvement (14-day) 3.53 [1.19, 10.46]> 10%2 studies (2/-)98.9 %some concernnot evaluable moderateimportant-
viral clearance 6.97 [0.23, 210.35]> 189%2 studies (2/-)86.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 7.68 [0.34, 173.70]> 190%2 studies (2/-)89.7 %some concernnot evaluable moderateimportant-
ICU admission 0.68 [0.41, 1.12]< 16%6 studies (6/-)93.5 %some concernnot evaluable moderatenon important-
off oxygenation 8.57 [1.43, 51.36]> 10%1 study (1/-)99.0 %NAnot evaluable non important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.36 [0.95, 1.94]< 116%9 studies (9/-)4.9 %some concernnot evaluable moderateimportant-
superinfection 0.77 [0.06, 9.89]< 176%2 studies (2/-)57.8 %highnot evaluable lowimportant-
adverse events 1.14 [0.92, 1.43]< 10%4 studies (4/-)11.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.